Ablynx NV (XBRU:ABLXS) EV-to-Revenue : 0.02 (As of Jun. 20, 2024)

View and export this data going back to . Start your Free Trial

What is Ablynx NV EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ablynx NV's enterprise value is €0.97 Mil. Ablynx NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2017 was €55.56 Mil. Therefore, Ablynx NV's EV-to-Revenue for today is 0.02.

The historical rank and industry rank for Ablynx NV's EV-to-Revenue or its related term are showing as below:

XBRU:ABLXS' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.6 Med: 6.9 Max: 46.6
Current: 59.35

During the past 12 years, the highest EV-to-Revenue of Ablynx NV was 46.60. The lowest was -0.60. And the median was 6.90.

XBRU:ABLXS's EV-to-Revenue is not ranked
in the Biotechnology industry.
Industry Median: 7.565 vs XBRU:ABLXS: 59.35

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-20), Ablynx NV's stock price is €0.00. Ablynx NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2017 was €1.29. Therefore, Ablynx NV's PS Ratio for today is 0.00.

Ablynx NV EV-to-Revenue Historical Data

The historical data trend for Ablynx NV's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV EV-to-Revenue Chart

Ablynx NV Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

EV-to-Revenue

Get a 7-Day Free Trial

4.39

5.96

9.36

6.01

24.01

Ablynx NV Semi-Annual Data
	Dec07	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17
EV-to-Revenue	Get a 7-Day Free Trial															9.36	-	6.01	-	24.01

Competitive Comparison of Ablynx NV's EV-to-Revenue

For the Biotechnology subindustry, Ablynx NV's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ablynx NV's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ablynx NV's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ablynx NV's EV-to-Revenue falls into.

Ablynx NV EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Ablynx NV's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	0.971	/	55.562
	=	0.02

Ablynx NV's current Enterprise Value is €0.97 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Ablynx NV's Revenue for the trailing twelve months (TTM) ended in Dec. 2017 was €55.56 Mil.

Ablynx NV (XBRU:ABLXS) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Ablynx NV's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.00	/	1.289
	=	0.00

Ablynx NV's share price for today is €0.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2017 was €1.29.

Ablynx NV EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ablynx NV's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Ablynx NV (XBRU:ABLXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.ablynx.com

Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV (XBRU:ABLXS) Headlines

No Headlines